EC approves Abraxane for pancreatic cancer

The European Commission approved an application to expand the label of Abraxane nab-paclitaxel from Celgene Corp. (NASDAQ:CELG) to include first-line treatment of metastatic pancreatic cancer in combination with gemcitabine. FDA approved Abraxane for the indication in September. Abraxane is already approved in more than 40 countries, including the U.S. and those of the EU, as second-line treatment of metastatic breast cancer. The albumin stabilized nanoparticle formulation of paclitaxel is also approved in the U.S., Argentina, Australia, Japan and New Zealand for first-line treatment of advanced non-small cell lung cancer (NSCLC). ...